Viridian Financial Statements From 2010 to 2026

Viridian Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 896.5 M 853.8 M 231.7 M Slightly volatile Short and Long Term Debt Total 25.5 M 24.3 M 11.6 M Pretty Stable Other Current Liabilities 54.3 M 51.7 M 13.8 M Slightly volatile Total Current Liabilities 57.8 M 55.1 M 20.4 M Slightly volatile Property Plant And Equipment Net 4.2 M 4 M 1.7 M Slightly volatile Current Deferred Revenue 246.2 K 259.2 K 1.3 M Pretty Stable Accounts Payable 2.1 M 2.5 M 1.7 M Slightly volatile Cash 120.3 M 114.5 M 47.4 M Slightly volatile Non Current Assets Total 2.7 M 4.5 M 2.4 M Slightly volatile Cash And Short Term Investments 866.5 M 825.2 M 223.1 M Slightly volatile Net Receivables 87.2 K 91.8 K 562.5 K Slightly volatile Common Stock Shares Outstanding 82 M 78.1 M 19.3 M Slightly volatile Liabilities And Stockholders Equity 896.5 M 853.8 M 231.7 M Slightly volatile Non Current Liabilities Total 27.6 M 26.3 M 8 M Slightly volatile Other Current Assets 25.2 M 24 M 6.2 M Slightly volatile Total Liabilities 85.4 M 81.4 M 28.2 M Slightly volatile Property Plant And Equipment Gross 5.7 M 5.4 M 2.3 M Slightly volatile Total Current Assets 891.7 M 849.2 M 229.2 M Slightly volatile Short Term Debt 438.6 K 461.7 K 4.9 M Slightly volatile Common Stock Total Equity 499.9 K 476.1 K 220.2 K Slightly volatile Common Stock 978.1 K 931.5 K 280.8 K Slightly volatile Property Plant Equipment 774.1 K 1.5 M 801.6 K Slightly volatile Other Liabilities 882 K 1.1 M 552.6 K Slightly volatile Long Term Debt 12.4 M 23.7 M 10.7 M Slightly volatile Non Current Liabilities Other 2.4 M 2.3 M 804.9 K Slightly volatile Net Working Capital 833.9 M 794.2 M 232 M Slightly volatile Short Term Investments 746.2 M 710.7 M 189.7 M Slightly volatile Short and Long Term Debt 3.4 M 4.6 M 3.1 M Slightly volatile Capital Stock 134.3 M 218.1 M 71.2 M Slightly volatile Capital Surpluse 502.8 M 852.2 M 375.8 M Slightly volatile Capital Lease Obligations 647.7 K 590 K 513.6 K Slightly volatile Preferred Stock Total Equity 121.8 M 127.9 M 164.6 M Slightly volatile Long Term Debt Total 3.7 M 4.2 M 4.6 M Slightly volatile
Viridian Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 1.5 M 1.4 M 436.9 K Slightly volatile Interest Expense 3.7 M 3.5 M 1.4 M Slightly volatile Selling General Administrative 73.8 M 70.2 M 25.9 M Slightly volatile Selling And Marketing Expenses 1.5 M 1.9 M 1.5 M Slightly volatile Total Revenue 258.2 K 271.8 K 3 M Slightly volatile Other Operating Expenses 361.4 M 344.2 M 104.3 M Slightly volatile Research Development 287.7 M 274 M 72.6 M Slightly volatile Cost Of Revenue 1.4 M 1.4 M 8.1 M Very volatile Total Operating Expenses 361.4 M 344.2 M 101.5 M Slightly volatile Interest Income 38.8 M 37 M 8 M Slightly volatile Reconciled Depreciation 343.6 K 621 K 330.6 K Slightly volatile Non Recurring 55.9 M 62.9 M 68.6 M Slightly volatile Non Operating Income Net Other 5.7 M 5.4 M 1.6 M Slightly volatile
Viridian Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Stock Based Compensation 50.9 M 48.5 M 15.9 M Slightly volatile Begin Period Cash Flow 124.2 M 118.3 M 43.2 M Slightly volatile Depreciation 652 K 621 K 289.7 K Slightly volatile Dividends Paid 17.5 M 16.7 M 5.6 M Slightly volatile Capital Expenditures 327 K 587.6 K 293.7 K Slightly volatile End Period Cash Flow 120.3 M 114.5 M 47.4 M Slightly volatile Change To Netincome 20.2 M 22.7 M 12.6 M Slightly volatile Issuance Of Capital Stock 578 M 550.5 M 154 M Slightly volatile Change Receivables 79.2 K 89.1 K 97.3 K Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 4.1 K 3.9 K 971 Slightly volatile Dividend Yield 0.0014 9.0E-4 0.001 Slightly volatile Days Sales Outstanding 72.68 136 76.9423 Very volatile Average Payables 50.7 K 57 K 62.2 K Slightly volatile Stock Based Compensation To Revenue 132 126 37.4263 Slightly volatile Capex To Depreciation 0.91 0.85 1.0591 Slightly volatile Inventory Turnover 37.62 35.83 30.8199 Slightly volatile Days Of Inventory On Hand 10.02 10.54 15.5262 Slightly volatile Payables Turnover 40.59 48.58 48.4581 Slightly volatile Sales General And Administrative To Revenue 191 182 55.0153 Slightly volatile Average Inventory 214.3 K 241 K 263.1 K Slightly volatile Research And Ddevelopement To Revenue 746 710 169 Slightly volatile Capex To Revenue 1.6 1.52 0.5055 Slightly volatile Cash Per Share 14.08 9.51 14.9196 Pretty Stable Days Payables Outstanding 18.89 9.94 12.6934 Very volatile Income Quality 0.57 0.77 0.7484 Slightly volatile Current Ratio 14.58 13.88 8.1429 Slightly volatile Receivables Turnover 2.63 2.77 27.5129 Very volatile Capex Per Share 0.0082 0.0087 0.2539 Slightly volatile Average Receivables 875.8 K 985.3 K 1.1 M Slightly volatile Revenue Per Share 0.0049 0.0051 8.3622 Slightly volatile Interest Debt Per Share 0.39 0.41 25.6508 Slightly volatile Debt To Assets 0.031 0.0327 1.5128 Slightly volatile Operating Cycle 85.61 136 87.7053 Pretty Stable Days Of Payables Outstanding 18.89 9.94 12.6934 Very volatile Ebt Per Ebit 1.98 1.04 1.7162 Pretty Stable Total Debt To Capitalization 0.0333 0.035 3.5231 Slightly volatile Quick Ratio 14.58 13.88 8.1276 Slightly volatile Net Income Per E B T 1.02 1.16 1.2608 Slightly volatile Cash Ratio 2.79 1.87 2.9401 Slightly volatile Days Of Inventory Outstanding 10.02 10.54 15.5262 Slightly volatile Days Of Sales Outstanding 72.68 136 76.9423 Very volatile Free Cash Flow Operating Cash Flow Ratio 1.12 1.15 1.0303 Slightly volatile Fixed Asset Turnover 0.0959 0.1 3.4716 Slightly volatile Debt Ratio 0.031 0.0327 1.5128 Slightly volatile Price Sales Ratio 4.1 K 3.9 K 971 Slightly volatile Asset Turnover 4.0E-4 5.0E-4 0.4601 Slightly volatile
Viridian Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 921.2 M 877.3 M 414.5 M Slightly volatile

Viridian Fundamental Market Drivers

Viridian Upcoming Events

About Viridian Therapeutics Financial Statements

Pair Trading with Viridian Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock:

How To Invest In Viridian Details

Is Viridian Stock a good investment? Details

What is Viridian Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details